Cadrenal Therapeutics (CVKD) investor relations material

Executive summary

• Focus shifted to developing CAD-1005 for immune-mediated and thrombotic disorders, with a pivotal Phase 3 trial planned following FDA guidance and regulatory milestones achieved, including End-of-Phase 2 meeting minutes and Orphan Drug and Fast Track designations.

• Advancing directly to a randomized, blinded, placebo-controlled Phase 3 trial for CAD-1005 in HIT, targeting NDA submission in 2029.

• Broader pipeline includes tecarfarin for chronic anticoagulation and frunexian for acute care settings, both in clinical stages.

• Recent warrant inducement raised $2.5 million, supporting operational runway and Nasdaq compliance.

Financial highlights

• Net loss for Q1 2026 was $2.5 million, a 35% improvement year-over-year from $3.8 million in Q1 2025.

• Operating expenses decreased 36% year-over-year to $2.5 million, driven by lower G&A and R&D costs.

• Cash and cash equivalents were $2.3 million as of March 31, 2026, down from $4.0 million at year-end 2025.

• Net cash used in operating activities was $3.0 million for Q1 2026.

• Weighted average shares outstanding increased to 2,407,665 from 1.8 million year-over-year.

Outlook and guidance

• Current cash resources expected to fund operations into October 2026, but insufficient for planned clinical trials.

• Additional capital will be sought through partnerships, ATM sales, equity, or debt; substantial doubt exists about ability to continue as a going concern without new funding.

• Phase 3 readiness activities are underway, with protocol finalization and further updates expected in coming quarters.

• The pivotal Phase 3 trial will enroll approximately 120 patients globally, with interim analysis planned.

• Projected NDA submission for CAD-1005 is targeted for 2029.